News Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- May 08, 2019NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (“Acerus” or “the Company”) (TSX:ASP; OTCQB:ASPCF) announced today its shares have been approved to be quoted on the OTCQB...
- May 07, 2019– Four Products Currently Under Review with the FDA –
DEER PARK, Ill., May 07, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products,...
- May 06, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP) will announce its first quarter 2019 financial and operating results on Monday May 13, 2019 before the market opens. The...
- May 06, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release first quarter 2019 financial and operating results on Thursday, May 9, 2019 after the close...
- May 02, 2019Transaction Creates Medical Device Company with Comprehensive Portfolio of Wound Care Solutions to Improve Healthcare Outcomes
FARMINGDALE, N.Y., May 02, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix”) a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical...
- May 01, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--May 1, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Apr 30, 2019
DEER PARK, Ill., April 30, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug...
- Apr 29, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP) (“Acerus” or the “Company”) today announced that it has engaged Paradigm Capital Inc. (“Paradigm”) as its...
- Apr 24, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (TSX:ASP) announced today that Edward Gudaitis, President and Chief Executive Officer of Acerus, is scheduled to present an overview...
- Apr 10, 2019
FARMINGDALE, N.Y., April 10, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices...
- Apr 09, 2019BIOLASE and TeamSmile Expand Initiative of Oral Health Day to Students in Kansas City Public SchoolsPlayers and mascot "Blue the Dog" from Sporting Kansas City will be in attendance to meet and greet the students and support the program
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, TeamSmile, the nation's premier advocacy group that supports life-changing dental care for underserved children, and the Sporting...
- Apr 03, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Apr. 3, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that
- Mar 29, 2019Total revenues of approximately $26.0 million for the fiscal year 2018 compared to $37.5 million for the fiscal year 2017.
Dallas, TX, March 29, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced its fourth quarter and full year...
- Mar 29, 2019NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (the “Company”) (TSX:ASP) is pleased to announce that it has closed a non-brokered private placement (the “Private Placement”)...
- Mar 27, 2019Chargers wide receiver Geremy Davis, running back Justin Jackson and the Charger Girls to meet the students and support necessary cause
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, TeamSmile, the nation's premier advocacy group that supports life-changing dental care for underserved children, and the Los...
- Mar 25, 2019NDA filing for ET-202 Accepted for Review and Assigned PDUFA Date of October 21, 2019
DEER PARK, Ill., March 25, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug...
- Mar 25, 2019-- Company Intends to Submit European MAA in Mid-2019 --
BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 25, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Mar 18, 2019-- If Approved, AR101 Will Be the First Medicine for This Life-Threatening Condition --
BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 18, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Mar 14, 2019FDA Previously Granted DS-200 Fast Track Designation
DEER PARK, Ill., March 14, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug...
- Mar 12, 2019
MIAMI, March 12, 2019 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and...
- Mar 11, 2019
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will be presenting at the second annual LD Micro Virtual Investor Conference on Wednesday, March 13th at...
- Mar 06, 2019
FARMINGDALE, N.Y., March 06, 2019 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices...
- Mar 05, 2019
BRISBANE, Calif.--(BUSINESS WIRE)--Mar. 5, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced...
- Mar 05, 2019Enteris’ lead program, Ovarest®, is designed to address a key endometriosis patient need by enabling the oral delivery of leuprolide
Boonton, NJ – March 5, 2019 – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary oral peptide delivery technologies, announced...
- Mar 05, 2019
TORONTO--(BUSINESS WIRE)-- Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX: ASP) today reported its financial results for the three and twelve-month period ended...